271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004288 (ClinicalTrials.gov) | May 1996 | 18/10/1999 | Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: olsalazine | National Center for Research Resources (NCRR) | University of Rochester | Completed | 18 Years | 65 Years | Male | 4 | Phase 2 | NULL |